A Single-Dose, Randomized, Open-Label, Two-Treatment, Two-Period, Two-Cohort, Crossover Study to Assess the Bioequivalence of Xian Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects Compared With Gurabo Risperdal Tablets
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Risperidone (Primary)
- Indications Aggression; Autistic disorder; Bipolar disorders; Dementia; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Xian-Janssen
- 27 Feb 2018 Planned primary completion date changed from 27 Apr 2018 to 2 Jan 2018.
- 27 Feb 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 21 Dec 2017 Status changed from not yet recruiting to recruiting.